Plain-English translation of NCT07048197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of treatment that uses your own immune cells to fight rheumatoid arthritis and Sjögren's disease. The study is looking at whether this medication is safe and how well it works in people whose conditions haven't improved with other standard treatments. Researchers will track your health closely to see how the treatment affects your disease.
Some people with rheumatoid arthritis or Sjögren's disease don't respond well to currently available medications, leaving them in pain with active disease. This trial is exploring whether this new cell-based treatment might offer hope for patients who have exhausted other options.
If you join this trial, you will receive a single infusion of the medication—your own immune cells that have been collected, processed in a laboratory, and returned to you. You will be closely monitored with blood tests and clinic visits to check your safety and how your body responds to the treatment. The study will track how long the cells stay active in your body and whether your arthritis or Sjögren's symptoms improve over time.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
France
Germany